Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03068468 · ClinicalTrials.gov registry record · Phase 2
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 490
- Enrollment target
NCT03068468 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 490 participants.
The verdict
NCT03068468, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 490 participants
- Enrollment target
Study Summary
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs leading to discontinuation, and Grade 3 \& 4 laboratory abnormalities. The Secondary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by the Clinical Global Impression of Change (CGI-C) at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) at Week 52 and to assess the impact of BIIB092 on quality of life, relative to placebo, as measured by change from baseline on the Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) at Week 52.
Interventions
- DRUG Placebo
- DRUG BIIB092
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03068468
The ClinicalTrials.gov registry entry for NCT03068468 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03068468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03068468 about?
NCT03068468 is a clinical study titled "Study of BIIB092 in Participants With Progressive Supranuclear Palsy". The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs ...
What is the current status of trial NCT03068468?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 490 participants. The study started on 2017-06-01. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT03068468?
The interventions under investigation include: Placebo (DRUG), BIIB092 (DRUG).
Who is sponsoring clinical trial NCT03068468?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.